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S U M M A R Y
Objectives: Human papillomavirus (HPV) infection is a major cause of premalignant dysplasia and
cervical cancer. There are no data on the prevalence of genotype-speciﬁc HPV infection assessed by HPV
E6/E7 mRNA in women representative of the Korean population across a broad age range.
Methods: A total of 630 women aged 17–90 years were enrolled in this study. ThinPrep liquid-based
cytology samples were evaluated using the CervicGen HPV RT-qDx assay, which detects 16 high-risk
(HR) HPV genotypes (set 1: HPV 16, 31, 33, 35, 52, and 58; set 2: HPV 18, 39, 45, 51, 59, and 68; and set 3:
HPV 53, 56, 66, and 69).
Results: The overall prevalence of HPV infection was 33.2% (n = 209), and oncogenic high-risk HPV was
detected in 75.9% (n = 107) of 141 women with high-grade cervical lesions. HPV 16 was the most
common HPV genotype among women with high-grade cervical lesions and histologically conﬁrmed
cervical intraepithelial neoplasia grade 2 and above (CIN2+) in the Republic of Korea (41.6%). Among
women aged over 30 years, 182/329 (55%) had invasive cervical cancer and 135 (74%) of these were
infected with oncogenic HR-HPV types (in particular 25% with HPV 16). Among patients diagnosed with
CIN2+, the positivity rate of HR-HPV was the highest in women aged 40–49 years.
Conclusions: These results suggest that the determination of speciﬁc HPV genotypes is very important
for evaluating the potential impact of preventive measures, including the use of prophylactic vaccines,
on reducing the burden of cervical cancer.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Cervical cancer, which develops from cervical intraepithelial
neoplasia (CIN), is the third most common malignancy in women
worldwide,1 and a major cause of morbidity and mortality.
Although the overall incidence of cervical cancer is declining,
493 000 new cases and 274 000 deaths due to cervical cancer occur
each year.1* Corresponding author. Tel.: +82 33 760 2740; fax: +82 33 760 2561.
E-mail address: hyelee@yonsei.ac.kr (H. Lee).
http://dx.doi.org/10.1016/j.ijid.2015.06.018
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Human papillomavirus (HPV) is the most common sexually
transmitted pathogen among women and men, and HPV infection
plays a central role in the etiology of cervical cancer.2 It has been
estimated that 70% of sexually active women will acquire an HPV
infection at some point during their lifetime. HPVs are small
double-stranded DNA viruses that infect basal cells and replicate
within the nucleus of squamous epithelial cells.3 Approximately
60 HPV genotypes are known to infect the genital tract,4 and
cervical cancer is caused by persistent infection with oncogenic
HPV genotypes that belong to a few phylogenetically related high-
risk (HR) species. Some HPV genotypes are able to infect cutaneous
tissues, resulting in the formation of warts on the hands or feet,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the genital epithelia are well characterized, and can be grouped as
HR species through their association with cervical cancer. As a
result, testing for oncogenic HPV infection in cervical lesions could
serve as an accurate means of identifying women who are at risk of
developing cervical cancer. Approximately 15 genotypes, including
HPV 16, 18, 33, 45, 52, 58, 39, 51, 56, and 59, are classiﬁed as HR-
HPV genotypes and are associated with cervical cancer or
precancerous lesions. In general, HPV types 16 and 18 cause
approximately 70% of cervical cancers and types 31, 33, 35, 45, 52,
and 58 account for an additional 20% of cases, although there is
substantial geographical variation in the relative frequencies of the
different HR types.5
HPV DNA positivity usually peaks in younger women, ranging
from 25% to 65% in women under 35 years of age, with a steady
decline to 10–30% in women older than 35 years.6 HPV DNA testing
has been suggested for the screening of women over 30 years of age
and for those with equivocal cytology results.7 The HR-HPV
genotypes express two major transforming genes encoding the E6
and E7 proteins, which are required for the immortalization of
human primary genital keratinocytes.8 These two oncogenes are
uniformly retained and highly expressed in cervical cancer cells,
and their continuous expression is required for retention of the
tumorigenic phenotype. The E6 and E7 proteins were initially
identiﬁed through their ability to target the p53 and retinoblasto-
ma protein (pRb) tumor suppressor pathways in host cells, thereby
interfering with cell cycle regulation.8 E7 stimulates the cell cycle
via its ability to bind and inactivate cellular pRb, whereas E6 binds
to p53 leading to degradation of p53 via the proteosomal
pathway.9–11
HPV prevalence has been found to be highest among young
persons within the ﬁrst few years of sexual activity.12 However,
there are few data on the prevalence of type-speciﬁc HPV infection
among HPV mRNA detected in women representative of the
Korean population across a broad age range.Table 1
Clinical samples used in this study
Cytological diagnosis Age, years, range (median) Number of 
SCC 44–90 (78) 45 (7.1) 
HSIL 26–79 (49) 72 (11.4) 
ASC-H 36–76 (53) 24 (3.8) 
LSIL 17–76 (50) 101 (16.0) 
ASC-US 26–80 (48) 100 (15.9) 
Normal (HR-HPV DNA-pos) 24–74 (45) 90 (14.3) 
Normal (HR-HPV DNA-neg) 198 (31.4) 
Total 630 (100.0)
ADC, adenocarcinoma; ASC-H, atypical squamous cells – cannot exclude HSIL; ASC-US, 
neoplasia; CIS, squamous cell carcinoma in situ; HPV, human papillomavirus; HR, high
intraepithelial lesion; ND, not done; SCC, squamous cell carcinoma.In the present study, the CervicGen HPV RT-qDx assay
(Optipharm, Osong, Republic of Korea), a commercial diagnostic
kit targeting HPV E6/E7 mRNA of 16 oncogenic HPV genotypes (set
1: HPV 16, 31, 33, 35, 52, and 58; set 2: HPV 18, 39, 45, 51, 59, and
68; and set 3: HPV 53, 56, 66, and 69), was used to investigate the
prevalence of all HR-HPV types in relation to age, cytology, and
histology of oncogenic HPV infection in Korean women using a
total of 630 ThinPrep Pap samples (Hologic Inc., Bedford, MA, USA).
2. Materials and methods
2.1. Clinical samples
Liquid-based cytology samples (Table 1) from 630 women were
obtained over a 2-year period (from June 2011 to July 2013) from
the Department of Pathology, Yonsei University Wonju Severance
Christian Hospital, Wonju, Republic of Korea. This study was
approved by the Institutional Ethics Committee at Yonsei
University Wonju College of Medicine (approval number
YWMR-12-4-010) and all subjects provided written informed
consent. All clinical samples were collected using ThinPrep Pap
materials (Hologic Inc.). The proportions of the different grades
included in this study were similar to those reported previously in
a meta-analysis on the HPV type distribution in Korean women.13
These samples included 45 squamous cell carcinomas (SCC),
72 high-grade squamous intraepithelial lesions (HSILs), 24 atypical
squamous cells – cannot exclude HSIL (ASC-H), 101 low-grade
squamous intraepithelial lesions (LSIL), 100 atypical squamous
cells of undetermined signiﬁcance (ASC-US), and 288 samples with
normal cytology. In this study, high-grade cervical lesions (i.e.,
lesions in which the cells appear very different from normal cells
and classiﬁed as CIN grade 2 or 3) with SCC, HSIL, and ASC-H
cytology, indicated major cytological abnormalities closely related




























atypical squamous cells of undetermined signiﬁcance; CIN, cervical intraepithelial
-risk; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous
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For liquid-based cytological smears, ThinPrep Pap tests (Hologic
Inc.) were carried out according to the manufacturer’s recom-
mendations. The clinical diagnosis was made primarily by two
cytopathologists using the 2001 Bethesda System terminology.
Cases with available tissue biopsies were reviewed by two
pathologists. After preparation of the Pap slide, 1 ml of exfoliated
cervical cell sample was transferred to each of two 1.5-ml
Eppendorf tubes and stored at 70 8C until use.
2.3. HPV DNA genotyping
The HPV genotyping assay was performed using the Goodgene
HPV chip (Goodgene Inc., Seoul, Republic of Korea) following the
manufacturer’s recommendations.14 The Goodgene HPV chip is
designed to detect 15 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 69, and 70) together with seven low-risk (LR)
HPV genotypes (6, 11, 34, 40, 42, 43, and 44). For the Goodgene HPV
chip, PCR products were loaded onto the probe-labeled glass chip
and the resulting signal was read using a GenePix Pro6.0 scanner
(Axon Instruments, Foster City, CA, USA).
2.4. PCR-reverse blot hybridization assay (PCR-REBA)
To conﬁrm the results of the RT-qPCR assays, the REBA HPV-ID
test (YD Diagnostic, Yongin, Republic of Korea) based on PCR-
REBA was performed according to the manufacturer’s instruc-
tions.14 For the REBA HPV-ID, hybridization and washing
processes were performed according to the manufacturer’s
instructions. In brief, the biotinylated PCR products were
denatured at 25 8C for 5 min in denaturation solution and diluted
in 970 ml of hybridization solution on the REBA membrane strip in
the blotting tray provided. Denatured single-stranded PCR
products were hybridized to the probes on a strip at 50 8C for
30 min. The strips were then washed twice with gentle shaking in
1 ml of washing solution for 10 min at 50 8C, incubated at 25 8C
with 1:2000 diluted streptavidin–alkaline phosphatase (AP)
conjugate (Roche Diagnostics, Mannheim, Germany) in conjugate
diluents solution (CDS) for 30 min, and ﬁnally washed twice with
1 ml CDS at room temperature for 1 min. The colorimetric
hybridization signals were visualized by the addition of a 1:50
dilution of AP-mediated staining solution, NBT/BCIP (Roche
Diagnostics), and incubation until a color change was detected.
Finally, the band pattern was read and interpreted.
2.5. Total RNA isolation
After cytology slide preparation was complete, the remainder
of the specimen was used for RNA isolation. Total cellular RNA
was isolated using the Isol-RNA Lysis Reagent (5 Prime, Austin,
TX, USA) according to the manufacturer’s instructions. Brieﬂy,
1 ml of the Isol-RNA Lysis Reagent (5 Prime) was added to the
cellular pellet. Cells were lysed by vortexing or repeated
pipetting, and left to stand at room temperature for 5 min.
Subsequently, 200 ml of chloroform was added and the mixture
was shaken vigorously and incubated at room temperature for
3 min before centrifugation at 12 000  g for 15 min. The
resultant aqueous layer was transferred to a new tube and an
equal volume of isopropanol was added and mixed by inverting
the tube. After incubation for 10 min at 25 8C and centrifugation
at 12 000  g for 10 min, 1 ml of 75% ethanol was added to the
supernatant and mixed by tube inversion. Finally, the mixture
was centrifuged at 7500  g for 5 min, and the supernatant was
removed. The RNA pellet was dried and eluted in 30 ml of
diethylpyrocarbonate (DEPC)-treated water (Intron Biotechnol-ogy, Seoul, Republic of Korea). The purity and concentration of
total RNA were determined by measuring the absorbance at
260 and 280 nm using an Inﬁnite 200 reader (Tecan, Salzburg,
Austria). All steps in the preparation and handling of total RNA
were performed in a laminar ﬂow hood under RNase-free
conditions. The isolated total RNA was stored at 70 8C.
2.6. cDNA synthesis
Complementary DNA (cDNA) was synthesized using an M-MLV
Reverse Transcriptase kit (Invitrogen, Carlsbad, CA, USA) and
random hexamers (Invitrogen) according to the manufacturer’s
recommendations. Brieﬂy, 10 ml of total RNA was added to Master
Mix containing 1 ml of 10 mM dNTP mix (10 mM each dATP, dGTP,
dCTP, and dTTP at a neutral pH), 0.25 mg of random hexamers, and
5 ml of DEPC-treated water in PCR tubes. The reaction mixture was
incubated at 65 8C for 5 min and quickly chilled on ice. After the
addition of 4 ml of 5 First-Strand Buffer, 2 ml of 0.1 M
dithiothreitol (DTT), and 1 ml of M-MLV reverse transcriptase
(RT), the cDNA synthesis reaction was performed at 25 8C for
10 min, 37 8C for 50 min, and 70 8C for 15 min.
2.7. HPV E6/E7 mRNA RT-qPCR assay
Detection of HPV E6/E7 mRNA in cervical specimens was
performed by quantitative reverse transcriptase PCR (RT-qPCR).
The RT-qPCR TaqMan assay was carried out with the CervicGen
HPV RT-qDx assay kit (Optipharm) using CFX-96 (Bio-Rad,
Hercules, CA, USA) real-time PCR systems for thermocycling
and ﬂuorescence detection, according to the manufacturers’
instructions. PCR primers and corresponding TaqMan probes were
designed for three different sets of HPVs, in each case targeting
their common sequence: (1) set 1: HPV genotypes 16, 31, 33, 35,
52, and 58; (2) set 2: HPV genotypes 18, 39, 45, 51, 59, and 68; and
(3) set 3: HPV genotypes 53, 56, 66, and 69. Real-time PCR
ampliﬁcation for HPV E6/E7 mRNA was performed using a total
volume of 25 ml containing 12.5 ml of 2  Thunderbird probe qPCR
mix (Toyobo, Osaka, Japan), 7.5 ml of primer and TaqMan probe
mixture, 5 ml of template cDNA, and distilled water (DW) to give a
ﬁnal volume of 25 ml for each sample. The multiplex RT-qPCR
assay detected HPV E6/E7 genes simultaneously in a single tube by
incorporating three target-speciﬁc TaqMan probes, which were
labeled with different ﬂuorophores (FAM, HEX, and Cy5). Positive
and negative controls were included throughout the procedure.
No-template controls with sterile DW instead of template DNA
were incorporated into each run. Cycling conditions were 95 8C for
3 min, followed by 45 cycles of 95 8C for 20 s and 60 8C for 40 s. The
mRNA expression level was quantiﬁed by determining the cycle
threshold (Ct), which is the number of PCR cycles required for the
ﬂuorescence to exceed a value signiﬁcantly higher than the
background ﬂuorescence. To avoid false-negatives due to
degradation of mRNA, glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as a control. Target gene mRNA
expression levels relative to GAPDH were calculated automati-
cally using the comparative Ct method by CFX Manager software
v1.6 (Bio-Rad).
2.8. Statistical analysis
All statistical analyses were performed using GraphPad Prism
5 software (GraphPad, La Jolla, CA, USA) and IBM SPSS software
version 21.0 (IBM Corp., Armonk, NY, USA). The sensitivity,
speciﬁcity, correlation p-value, and 95% conﬁdence interval (CI)
of the predictive ability for each HPV DNA chip or REBA HPV-ID and
CervicGen HPV RT-qDx assay were estimated with respect to the
cytological and histological diagnosis.
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3.1. Cytological and histological diagnosis
The clinical characteristics of the patients are shown in
Table 1. The age range of patients was 17 to 90 years, with a
mean age of 48.2  12.4 years (95% conﬁdence interval (CI) 47.43–
49.54 years). Among 630 cytology samples, 259 were conﬁrmed
histologically using biopsy or excision specimens. Of these, 45 cases
were identiﬁed as SCC, 72 as high-grade HSIL, 24 as ASC-H, 101 as
LSIL, 100 as ASC-US, 90 as cytology normal but HR-HPV DNA-positive,
and 198 as normal and HR-HPV DNA-negative (Table 1). Among all
women with different cytological diagnoses and a valid HPV test, 259
(75.7%) also had a valid histology result. Of these, 187 (54.7%) were
diagnosed with histologically conﬁrmed CIN2, CIN3, or SCC, 64
(24.4%) were diagnosed with invasive cervical cancer, and 288 (45.7%)
had a conﬁrmed negative ﬁnding on colposcopy and/or histology.
3.2. Positivity of HPV E6/E7 mRNA expression in different cytological
diagnoses
In order to determine the positivity of E6/E7 mRNA expression
of the different HR-HPV groups, HR-HPV genotypes were grouped
as set 1 (HPV 16, 31, 33, 35, 52, and 58), set 2 (HPV 18, 39, 45, 51, 59,Figure 1. (A) Overall prevalence of HR-HPV set 1 (HPV 16, 31, 33, 35, 52, and 58), set
2 (HPV 18, 39, 45, 51, 59, and 68), and set 3 (HPV 53, 56, 66, and 69) by HPV mRNA
assay. (B) Prevalence of HR-HPV sets according to the cytological grade of lesions
(high–low).and 68), and set 3 (HPV 53, 56, 66, and 69). Figure 1 shows the
prevalence of the HR-HPV groups based-on the E6/E7 mRNA
expression by each set in the HPV mRNA assay. The most common
HR-HPV group across all ages was set 1 (overall prevalence 59.5%),
followed by set 3 (24.2%) and set 2 (16.4%). Among the 160 HR-HPV
set 1-positive samples, 121 (71.6%) were high-grade, 36 (37.1%)
were low-grade, and three (1%) were normal cytology lesions.
Corresponding values for high- and low-grade lesions in the other
groups were 29 (17.2%) and 15 (15.5%) among 44 HR-HPV set
2 samples, and 19 (11.2%) and 46 (47.4%) among 65 HR-HPV set
3 samples. Figure 2 represents the prevalence of HR-HPV sets 1, 2,
and 3 by HPV E6/E7 mRNA and HPV DNA assays according to
cytological grade. The set 1 group accounted for up to 84% and
63.9% of high-grade cytological cervical lesions by HPV mRNA and
DNA test, respectively.
3.3. Comparison between positivity of HPV E6/E7 mRNA expression
and HPV DNA in different cytological diagnoses
The prevalence rates of HR-HPV sets 1, 2, and 3 by HPV E6/E7
mRNA and HPV DNA assays according to the cytological grade were
compared. Prevalence rates of HR-HPV set 1 in the HPV E6/E7
mRNA assay were 73.4% (n = 39) for SCC, 65.5% (n = 66) for HSIL,
57.1% (n = 16) for ASC-H, 16.1% (n = 21) for LSIL, 15.8% (n = 16) for
ASC-US, and 1.1% (n = 3) for normal samples. For HR-HPV set
2 group, rates were 9.7% (n = 5) for SCC, 13.3% (n = 22) for HSIL, 7.6%
(n = 2) for ASC-H, 9.9% (n = 13) for LSIL, and 3.3% (n = 2) for ASC-US.
For HR-HPV set 3, rates were 5.8% (n = 2) for SCC, 15.5% (n = 11) for
HSIL, 22.8% (n = 6) for ASC-H, 27.5% (n = 36) for LSIL, and 8.8%
(n = 10) for ASC-US (Figure 2A).
Prevalence rates for HR-HPV set 1 in the HPV DNA assay were
75.9% (n = 34) for SSC, 62.1% (n = 46) for HSIL, 43.8% (n = 12) for
ASC-H, 11.7% (n = 14) for LSIL, 11% (n = 17) for ASC-US, and 4.2%
(n = 39) for normal samples. For HR-HPV set 2, these were 10.9%
(n = 2) for SCC, 12.2% (n = 9) for HSIL, 7.3% (n = 2) for ASC-H, 7.5%
(n = 9) for LSIL, 6% (n = 9) for ASC-US, and 1.7% (n = 16) for normal
samples. For HR-HPV set 3, these were 4.1% (n = 3) for HSIL, 5.8%
(n = 7) for LSIL, and 0.8% (n = 7) for normal samples (Figure 2B).
3.4. Prevalence of HR-HPV genotypes based on E6/E7mRNA
expression in different cytological grades
Oncogenic HR-HPV was detected in 126 (89.4%) of 141 women
with high-grade cervical lesions and a valid HPV test (Table 2). The
most common HPV genotypes in descending order of prevalence
were HPV 16 (29.1%), 33 (14.6%), 58 (12.7%), 35 (10.9%), and 18
(7.3%) for CIN3 (Pearson correlation r-value = 0.95, p < 0.0001);
and HPV 16 (54.5%), 33 (18.2%), 31 (6.8%), 52 (6.8%), and 58 (4.6%)
for invasive cancers (r-value = 0.97, p < 0.0001) (Table 2). Co-
infection with other HR-HPV genotypes such as HPV 33, 58, 66, 35,
and 68 was observed in 31% of HPV 16-positive women. In
addition, oncogenic HPV was detected in 73 (36.3%) of 201 women
with low-grade cytology lesions and a valid HPV test (r-value =
0.90 p < 0.0001) (Table 2). In these women, prevalent HPV
genotypes detected were HPV 16 (4.5%), 68 (2.5%), 18 (2%), 56
(2%), 58 (1.5%), and 66 (1%).
3.5. Prevalence of HR-HPV genotypes based on E6/E7 mRNA
expression according to age
The distribution of HPV in the different age groups is shown in
Table 3 and Figure 3. HR-HPV genotype prevalence based on E6/E7
mRNA expression by age group in patients with cytologically and
histologically conﬁrmed CIN2+ lesions showed the highest rates in
women aged 40 to 49 years for high-grade lesions (24.1% for
cytologically conﬁrmed and 22.5% for histologically conﬁrmed;
Figure 2. Prevalence of HR-HPV sets 1, 2, and 3 by HPV E6/E7 mRNA (A) and HPV DNA (B) assays according to cytological grade.
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50 to 59 years for low-grade lesions (14.9% and 16% respectively,
Pearson correlation r-value = 0.925, p < 0.001). There was a
marked slight increase in the prevalence of HR-HPV with age, both
overall (52.7% (39/74) for those aged less than 30 years and 56.3%
(151/268) for those aged 30 years and above) and for each HPV
genotype. The age-speciﬁc HPV prevalence rate ranged between
1.9% and 33.3%. A signiﬁcant age-speciﬁc trend was observed in the
relative prevalence of HPV 16 versus other HR-HPV genotypes in
women with histologically conﬁrmed CIN2+ lesions. In women
under 30 years of age, the most prevalent HPV genotype detected
was HPV 16 (31.1%), followed by HPV 52 (8.9%), 18 (6.7%), 31, 56,
58, and 66 (each 4.4%), and 33 (2.2%). Among women aged 40 and
over, the most prevalent HPV genotype detected was also HPV 16
(27.2%), followed by 33 (10.8%), 58 (8.9%), 35 (4.4%), 18 (4.4%), 31
(3.2%), 56 (3.2%), 68 (3.2%), 52 (1.9%), 66 (0.6%), and 69 (0.6%).
4. Discussion
HPV DNA testing has been shown to have signiﬁcantly higher
sensitivity than Pap cytological smear examination for the
detection of high-grade cervical lesions including CIN2, CIN3,
SCC, endocervical adenocarcinoma (ADC) in situ, and endocervical
ADC. Although current DNA testing methods for HR-HPV provideadequate analytical sensitivity, their low speciﬁcity leads to false-
positive results and unnecessary invasive procedures such as
colposcopy and biopsy.15 E6 and E7 mRNA expression levels of HPV
have been found to increase with lesion severity, therefore the
detection of HPV E6/E7 mRNA expression might be of greater
prognostic value and might improve the speciﬁcity and positive
predictive value (PPV) compared with HPV DNA testing used in
traditional cervical cancer screening.16–18
In this study, it was found that the positivity of HPV E6/E7
mRNA expression was signiﬁcantly lower than HPV DNA positivity,
detecting an overall HPV prevalence of 58.2% if unclassiﬁed types
were included and 40.9% for only the 16 speciﬁc HR- HPV
genotypes that are typically tested for. This difference was
particularly evident in clinically negative, histologically negative
CIN1 samples and in normal samples, in concordance with the
results of previous studies.19 The present results showed that HPV
DNA testing was positive in 90/288 (31.3%) normal cytology
samples, whereas the HPV E6/E7 mRNA assay was positive in only
3/288 (1%) of these samples. In cases of cervical cancer, the
oncogenic process is initiated and mediated by the upregulation of
HPV E6/E7 oncoproteins. The HPV E6/E7 mRNA assay showed 91%
sensitivity (128/141) and 93% speciﬁcity (111/120) in samples of
histologically conﬁrmed CIN2+ from high-grade cervical lesions
and malignancy (Pearson correlation r-value = 0.993, p < 0.001).
Table 2
Type-speciﬁc prevalence of oncogenic HPV infection in women with a high-grade cytology (ASC-H/HSIL/SCC), histologically conﬁrmed grade CIN2, CIN3, ADC and SCC, low-
grade cytology (LSIL/ASC-US) with CIN2+, and normal cytology samples.






















16 49 (34.7) 48 (34) 2 (15.4) 16 (29.1) 24 (54.5) 17 (8.5) 9 (4.5) 1 (3.7) 24 (8.3) 1 (33.3)
33 18 (12.7) 17 (12.1) 0 (0) 8 (14.6) 8 (18.2) 3 (1.5) 0 (0) 1 (3.7) 5 (1.7) 0 (0)
58 14 (9.9) 14 (9.9) 3 (23.1) 7 (12.7) 2 (4.6) 4 (2) 3 (1.5) 2 (7.4) 5 (1.7) 0 (0)
31 7 (4.9) 7 (5) 1 (7.7) 2 (3.6) 3 (6.8) 1 (0.5) 0 (0) 0 (0) 1 (0.3) 1 (33.3)
35 6 (4.3) 6 (4.3) 1 (7.7) 6 (10.9) 0 (0) 2 (1) 1 (0.5) 0 (0) 0 (0) 0 (0)
52 6 (4.3) 6 (4.3) 0 (0) 2 (3.6) 3 (6.8) 5 (2.5) 1 (0.5) 0 (0) 3 (1.0) 1 (33.3)
Set 2 group
18 8 (5.7) 6 (4.3) 1 (7.7) 4 (7.3) 0 (0) 10 (5) 4 (2) 2 (7.4) 10 (3.5) 0 (0)
68 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (3) 5 (2.5) 1 (3.7) 5 (1.7) 0 (0)
39 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1.5) 1 (0.5) 1 (3.7) 1 (0.3) 0 (0)
Set 3 group
56 3 (2.1) 3 (2.1) 2 (15.4) 0 (0) 0 (0) 4 (1.9) 4 (2) 1 (3.7) 4 (1.4) 0 (0)
66 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1.5) 2 (1) 1 (3.7) 3 (1.0) 0 (0)
69 0 (0) 0 (0) 0 (0) 2 (3.6) 0 (0) 0 (0) 0 (0) 1 (3.7) 1 (0.3) 0 (0)
Other 6 (4.3) 3 (2.1) 0 (0) 0 (0) 0 (0) 74 (36.8) 20 (10) 7 (26) 4 (1.4) 0 (0)
Negative 6 (4.3) 0 (0) 0 (0) 0 (0) 1 (2.3) 48 (23.9) 10 (5) 5 (18.5) 198 (68.8) 0 (0)
Multi-infection 18 (12.8) 16 (11.3) 3 (23.1) 8 (14.6) 3 (6.8) 21 (10.4) 13 (6.5) 4 (14.8) 24 (8.3) 0 (0)
16 included 7 (5.0) 6 (4.8) 2 (15.4) 3 (5.5) 1 (2.3) 5 (2.5) 4 (5.5) 2 (7.4) 4 (1.4) -
18 included 2 (1.4) 2 (1.6) 0 (0) 2 (3.6) 0 (0) 3 (1.5) 1 (1.4) 0 (0) 5 (1.7) -
16 and 18 both included 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (2.0) 0 (0) 0 (0) 10 (3.5) -
Other genotypes 9 (6.4) 8 (6.3) 1 (7.7) 3 (5.5) 3 (6.8) 9 (4.5) 8 (11.0) 2 (7.4) 5 (1.7) -
Total 141 (100) 126 (89.4) 13 (100) 55 (100) 44 (100) 201 (100) 73 (36) 27 (100) 288 (100) 3 (1)
ADC, adenocarcinoma; ASC-H, atypical squamous cells – cannot exclude HSIL; ASC-US, atypical squamous cells of undetermined signiﬁcance; CIN, cervical intraepithelial
neoplasia; HPV, human papillomavirus; HR, high-risk; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; SCC, squamous cell
carcinoma.
a CIN3 (Pearson correlation r-value = 0.95, p < 0.0001).
b Invasive cancers (Pearson correlation r-value = 0.997, p < 0.0001).
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is associated with a signiﬁcantly increased risk of CIN and cervical
cancer.20 Therefore, the detection of E6/E7 oncogene expression
levels could be more speciﬁc and a better predictor of cervical
cancer risk than the detection of HPV DNA.21
Although the prevalence of HPV among sub-groups of patients
classiﬁed by disease severity varies, the overall prevalence of HPV
in women with cervical cancer approaches 95–100%.2 Among the
100 HPV genotypes that have been identiﬁed to date, certain ones
of the HR-HPV group have been associated strongly with cervical
cancer;22 HPV 16, 18, 45, 31, 33, 52, 58, and 35 are the mostTable 3
Prevalence of type-speciﬁc oncogenic HPV infection in women of different ages
with high-low cytological grades and histologically conﬁrmed CIN2+
HR-HPV genotypes Age group
<30s (n = 74) 40s (n = 99) 50s (n = 101) >60s (n = 68)
Set 1 group
16 14 (31.1) 18 (33.3) 15 (26.3) 10 (21.3)
31 2 (4.4) 3 (5.6) 0 (0) 2 (4.3)
33 1 (2.2) 4 (7.4) 6 (10.5) 7 (14.9)
35 0 (0) 2 (3.7) 3 (5.3) 2 (4.3)
52 4 (8.9) 0 (0) 2 (3.5) 1 (2.1)
58 2 (4.4) 3 (5.6) 3 (5.3) 8 (17.0)
Set 2 group
18 3 (6.7) 1 (1.9) 1 (1.8) 5 (10.6)
45 0 (0) 0 (0) 0 (0) 0 (0)
39 0 (0) 0 (0) 1 (1.8) 0 (0)
68 0 (0) 2 (3.7) 3 (5.3) 0 (0)
Set 3 group
56 2 (4.4) 1 (1.9) 4 (7.0) 0 (0)
66 2 (4.4) 1 (1.9) 0 (0) 0 (0)
69 0 (0) 1 (1.9) 0 (0) 0 (0)
Multiple 6 (13.3) 9 (16.7) 6 (10.5) 7 (14.9)
Others 3 (6.7) 8 (14.8) 9 (15.8) 3 (6.4)
Negative 6 (13.3) 1 (1.9) 4 (7.0) 2 (4.3)
Total 45 54 57 47
HPV, human papillomavirus; CIN, cervical intraepithelial neoplasia; HR, high-risk.prevalent genotypes among cervical cancers, in particular HPV
16 and 18.23
In this study, the overall positivity of HPV infection was
33.2% (209/630), which is higher than that reported previously
in most countries,24–26 and 45.7% of women had normal
cytology. The most common HPV genotypes detected in most
previous European studies were HPV 16 and 3125,26 and in the
USA were HPV 16, 45, and 51,27 whereas the present study
showed the most prevalent HPV genotypes in Korean patients to
be HPV 16, 33, and 58. The prevalence of the HR-HPV set 1 group
among all groups was 98/141 (61.7%), and the set 1 group
accounted for up to 84% and 63.9% of high-grade cervical lesions
by HPV mRNA and DNA test, respectively. This result was
statistically more signiﬁcant for the HPV E6/E7 mRNA test than
the HPV DNA test for high-grade cytological lesions. However,
the HR-HPV set 3 group showed a higher prevalence than the set
1 group (22.9% vs. 17.9%) in low-grade cytological lesions by the
HPV mRNA test, although there was no signiﬁcant difference by
the HPV DNA test (Figure 2). HPV 16 is the most frequent HPV
genotype among women with high-grade cervical lesions and
women with histologically conﬁrmed CIN2+. The results of the
present study also showed that the overall prevalence of
oncogenic HPV 16 was 33.9% (57/168) among patients with
different cytology grades in Korea. This result is broadly
consistent with the reported rate of less than 40% in patients
from North America, Asia, and South/Central America.28 The
combined prevalence of oncogenic HPV 16 and 18 was 38.7%
among women with a high-grade cytology cervical lesion, 23% in
women with histologically conﬁrmed CIN2, and 45.9% in those
with conﬁrmed CIN3. Several HR- HPV genotypes other than
HPV 16/18, such as HPV 31, 33, 52, and 58 that are included in
the HR- HPV set 1 group of HPV E6/E7 mRNA, were relatively
prevalent in the Republic of Korea.
Other studies have shown HPV positivity to be highest among
women aged less than 20 years.24,25 Results from this study were
Figure 3. Prevalence of positivity for HPV E6/E7 mRNA in cytologically conﬁrmed (A) and histologically conﬁrmed (B) CIN2+ lesions according to patient age. Pearson
correlation was used to analyze differences between age groups in high-grade lesions (r-value = 0.993, p < 0.001) and low-grade lesions (r-value = 0.925, p < 0.001).
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because only 12 samples were tested. Among women aged
30 years and over, a total of 182/329 (55%) had progressed to
invasive cervical cancer and 135 (74%) of these patients were
infected with oncogenic HR-HPV genotypes (in particular 35.6%
(n = 48) with HPV 16 and 40% (n = 54) with multiple infection
including HPV 16). The prevalence of CIN2+ cases was similar in
women aged less than 30 years and more than 30 years, whereas
CIN3+ cases were more common in women over 30 years of age
and were present in only ﬁve patients in their 20s (especially in
cervical cancer). The prevalence of any conﬁrmed HR-HPV
genotype by HPV E6/E7 mRNA in patients with CIN2+ lesions
was highest in women aged 40 to 49 years (38.9%) and 50 to
59 years (36.8%). In general, invasive cervical cancer cases are
diagnosed between the ages of 35 and 55 years. This distribution is
due to the fact that cervical cancers originate mainly from HPV
infections transmitted sexually in early adulthood or late
adolescence and these may then progress to invasive disease over
5–10 years.29
To conclusively show the prevalence of oncogenic HPV types it
will be necessary to carry out more tests with a larger number ofpatients and a wider age distribution in other areas of the Republic
of Korea. Although vaccine-targeted HPV 16 and 18 are the most
frequent HPV genotypes worldwide and have also been shown to
be associated with cancer, the extent to which vaccines directed
against HPV 16 and 18 may prevent disease associated with other
HPV genotypes is not yet clear. In addition to HPV 16, it is necessary
to develop vaccines to other oncogenic genotypes. The differences
in HPV prevalence and genotype distribution identiﬁed in this
study have a potential inﬂuence on the effectiveness of HPV
vaccines for cervical cancer and the development of screening
programs, which should be investigated in future studies.
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